SOSV

Plantruption builds a brand of sustainability to develop products using seaweed and microalgae. The company is on a mission to create the first plant-based seafood. It researches and collaborates with universities and food technologists to provides Plant-based seafood that’s close in taste and texture to the real deal. Plant-based seafood provides a host of environmental benefits, including alleviating pressures on rapidly depleting fisheries, providing relief to fragile ocean ecosystems, reducing the impact of fishing nets on the ocean plastic problem, and reducing production emissions. The company was founded in 2019 in Dublin, Dublin.

Prospective Research, Inc. is a biotechnology company based in Beverly, Massachusetts, focused on developing innovative solutions for the aquaculture industry and antibiotic discovery. Established in 2015, the company utilizes its advanced technology platforms, including MicrobeMiner and GeneMiner, to access untapped antibiotics from soil-dwelling microbes. By employing microbial signaling molecules, Prospective Research creates feed incorporated preventative disease management solutions that eliminate the need for traditional antibiotics and medicated feed. Their approach involves modulating bacterial behavior and introducing trillions of beneficial bacteria into the microbiomes of farmed species such as fin-fish, shrimp, and shellfish. This technology enables the selective activation of genes that produce bio-active therapeutics, offering protection against various pathogens while enhancing the health of aquaculture species.

Plantruption builds a brand of sustainability to develop products using seaweed and microalgae. The company is on a mission to create the first plant-based seafood. It researches and collaborates with universities and food technologists to provides Plant-based seafood that’s close in taste and texture to the real deal. Plant-based seafood provides a host of environmental benefits, including alleviating pressures on rapidly depleting fisheries, providing relief to fragile ocean ecosystems, reducing the impact of fishing nets on the ocean plastic problem, and reducing production emissions. The company was founded in 2019 in Dublin, Dublin.

Plantruption builds a brand of sustainability to develop products using seaweed and microalgae. The company is on a mission to create the first plant-based seafood. It researches and collaborates with universities and food technologists to provides Plant-based seafood that’s close in taste and texture to the real deal. Plant-based seafood provides a host of environmental benefits, including alleviating pressures on rapidly depleting fisheries, providing relief to fragile ocean ecosystems, reducing the impact of fishing nets on the ocean plastic problem, and reducing production emissions. The company was founded in 2019 in Dublin, Dublin.

Plantruption builds a brand of sustainability to develop products using seaweed and microalgae. The company is on a mission to create the first plant-based seafood. It researches and collaborates with universities and food technologists to provides Plant-based seafood that’s close in taste and texture to the real deal. Plant-based seafood provides a host of environmental benefits, including alleviating pressures on rapidly depleting fisheries, providing relief to fragile ocean ecosystems, reducing the impact of fishing nets on the ocean plastic problem, and reducing production emissions. The company was founded in 2019 in Dublin, Dublin.

BioFeyn focuses on enhancing aquaculture by optimizing the feed for farmed fish. The company employs a specialized method of biodegradable nanoencapsulation that surrounds trace amounts of marine ingredients with naturally-derived compounds. This innovative approach improves digestion, absorption, and bioavailability of nutrients, ensuring that fish receive what they naturally consume in the ocean. By delivering essential nutrients and natural disease preventatives through a targeted delivery mechanism, BioFeyn aims to improve fish health and reduce environmental pollution. This method not only contributes to the sustainability of fish farming but also helps produce more nutritious fish for consumers.

BioFeyn focuses on enhancing aquaculture by optimizing the feed for farmed fish. The company employs a specialized method of biodegradable nanoencapsulation that surrounds trace amounts of marine ingredients with naturally-derived compounds. This innovative approach improves digestion, absorption, and bioavailability of nutrients, ensuring that fish receive what they naturally consume in the ocean. By delivering essential nutrients and natural disease preventatives through a targeted delivery mechanism, BioFeyn aims to improve fish health and reduce environmental pollution. This method not only contributes to the sustainability of fish farming but also helps produce more nutritious fish for consumers.

MicroSynbiotiX Limited is a biotechnology company based in Cork City, Ireland, that specializes in developing oral vaccines tailored for the aquaculture sector. Founded in 2016, the company focuses on addressing the challenges posed by excessive antibiotic use in farmed fish. Through advancements in algal genomics and molecular biology, MicroSynbiotiX engineers microalgae to produce cost-effective therapeutic proteins and vaccines. This innovative approach utilizes microalgae as an oral delivery system, significantly reducing production costs and labor associated with traditional vaccine methods. The technology aims to decrease fish mortality rates, prevent bacterial and viral diseases that threaten fish stocks, and enhance global food security by providing affordable and user-friendly solutions for aquaculture.

MicroSynbiotiX Limited is a biotechnology company based in Cork City, Ireland, that specializes in developing oral vaccines tailored for the aquaculture sector. Founded in 2016, the company focuses on addressing the challenges posed by excessive antibiotic use in farmed fish. Through advancements in algal genomics and molecular biology, MicroSynbiotiX engineers microalgae to produce cost-effective therapeutic proteins and vaccines. This innovative approach utilizes microalgae as an oral delivery system, significantly reducing production costs and labor associated with traditional vaccine methods. The technology aims to decrease fish mortality rates, prevent bacterial and viral diseases that threaten fish stocks, and enhance global food security by providing affordable and user-friendly solutions for aquaculture.

Prospective Research, Inc. is a biotechnology company based in Beverly, Massachusetts, focused on developing innovative solutions for the aquaculture industry and antibiotic discovery. Established in 2015, the company utilizes its advanced technology platforms, including MicrobeMiner and GeneMiner, to access untapped antibiotics from soil-dwelling microbes. By employing microbial signaling molecules, Prospective Research creates feed incorporated preventative disease management solutions that eliminate the need for traditional antibiotics and medicated feed. Their approach involves modulating bacterial behavior and introducing trillions of beneficial bacteria into the microbiomes of farmed species such as fin-fish, shrimp, and shellfish. This technology enables the selective activation of genes that produce bio-active therapeutics, offering protection against various pathogens while enhancing the health of aquaculture species.

MicroSynbiotiX Limited is a biotechnology company based in Cork City, Ireland, that specializes in developing oral vaccines tailored for the aquaculture sector. Founded in 2016, the company focuses on addressing the challenges posed by excessive antibiotic use in farmed fish. Through advancements in algal genomics and molecular biology, MicroSynbiotiX engineers microalgae to produce cost-effective therapeutic proteins and vaccines. This innovative approach utilizes microalgae as an oral delivery system, significantly reducing production costs and labor associated with traditional vaccine methods. The technology aims to decrease fish mortality rates, prevent bacterial and viral diseases that threaten fish stocks, and enhance global food security by providing affordable and user-friendly solutions for aquaculture.

Prospective Research, Inc. is a biotechnology company based in Beverly, Massachusetts, focused on developing innovative solutions for the aquaculture industry and antibiotic discovery. Established in 2015, the company utilizes its advanced technology platforms, including MicrobeMiner and GeneMiner, to access untapped antibiotics from soil-dwelling microbes. By employing microbial signaling molecules, Prospective Research creates feed incorporated preventative disease management solutions that eliminate the need for traditional antibiotics and medicated feed. Their approach involves modulating bacterial behavior and introducing trillions of beneficial bacteria into the microbiomes of farmed species such as fin-fish, shrimp, and shellfish. This technology enables the selective activation of genes that produce bio-active therapeutics, offering protection against various pathogens while enhancing the health of aquaculture species.

MicroSynbiotiX Limited is a biotechnology company based in Cork City, Ireland, that specializes in developing oral vaccines tailored for the aquaculture sector. Founded in 2016, the company focuses on addressing the challenges posed by excessive antibiotic use in farmed fish. Through advancements in algal genomics and molecular biology, MicroSynbiotiX engineers microalgae to produce cost-effective therapeutic proteins and vaccines. This innovative approach utilizes microalgae as an oral delivery system, significantly reducing production costs and labor associated with traditional vaccine methods. The technology aims to decrease fish mortality rates, prevent bacterial and viral diseases that threaten fish stocks, and enhance global food security by providing affordable and user-friendly solutions for aquaculture.

Prospective Research, Inc. is a biotechnology company based in Beverly, Massachusetts, focused on developing innovative solutions for the aquaculture industry and antibiotic discovery. Established in 2015, the company utilizes its advanced technology platforms, including MicrobeMiner and GeneMiner, to access untapped antibiotics from soil-dwelling microbes. By employing microbial signaling molecules, Prospective Research creates feed incorporated preventative disease management solutions that eliminate the need for traditional antibiotics and medicated feed. Their approach involves modulating bacterial behavior and introducing trillions of beneficial bacteria into the microbiomes of farmed species such as fin-fish, shrimp, and shellfish. This technology enables the selective activation of genes that produce bio-active therapeutics, offering protection against various pathogens while enhancing the health of aquaculture species.

MicroSynbiotiX Limited is a biotechnology company based in Cork City, Ireland, that specializes in developing oral vaccines tailored for the aquaculture sector. Founded in 2016, the company focuses on addressing the challenges posed by excessive antibiotic use in farmed fish. Through advancements in algal genomics and molecular biology, MicroSynbiotiX engineers microalgae to produce cost-effective therapeutic proteins and vaccines. This innovative approach utilizes microalgae as an oral delivery system, significantly reducing production costs and labor associated with traditional vaccine methods. The technology aims to decrease fish mortality rates, prevent bacterial and viral diseases that threaten fish stocks, and enhance global food security by providing affordable and user-friendly solutions for aquaculture.

Prospective Research, Inc. is a biotechnology company based in Beverly, Massachusetts, focused on developing innovative solutions for the aquaculture industry and antibiotic discovery. Established in 2015, the company utilizes its advanced technology platforms, including MicrobeMiner and GeneMiner, to access untapped antibiotics from soil-dwelling microbes. By employing microbial signaling molecules, Prospective Research creates feed incorporated preventative disease management solutions that eliminate the need for traditional antibiotics and medicated feed. Their approach involves modulating bacterial behavior and introducing trillions of beneficial bacteria into the microbiomes of farmed species such as fin-fish, shrimp, and shellfish. This technology enables the selective activation of genes that produce bio-active therapeutics, offering protection against various pathogens while enhancing the health of aquaculture species.